Artivion (NYSE:AORT) Reaches New 52-Week High – Should You Buy?

Artivion, Inc. (NYSE:AORT) shares reached a new 52-week high on Thursday . The stock traded as high as $32.33 and last traded at $32.25, with a volume of 304340 shares traded. The stock had previously closed at $30.06.

Analyst Ratings Changes

Several equities research analysts recently commented on AORT shares. Oppenheimer boosted their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $34.00 target price on shares of Artivion in a report on Monday, December 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Stock Performance

The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock’s 50-day simple moving average is $28.73 and its 200-day simple moving average is $27.07. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -1,577.50 and a beta of 1.74.

Insider Activity at Artivion

In other news, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now directly owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,017 shares of company stock valued at $600,007 over the last quarter. 8.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Artivion by 28.0% during the third quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after buying an additional 25,176 shares during the last quarter. Barclays PLC grew its holdings in Artivion by 346.3% during the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after purchasing an additional 54,996 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Artivion in the third quarter valued at $5,798,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Artivion by 543.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock worth $761,000 after acquiring an additional 24,130 shares during the period. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.